Home Tags Vaccine

Topic: Vaccine

Representational image | Flickr

Not Oxford lab, not US company, Covid solution will come from India, China pharma industry

Fast and mass pharma production in India and China is crucial if the coronavirus pandemic is to be brought under control.
Representational image | Pixabay

Are people who have had Covid-19 immune? Perhaps not

What needs to happen now is a series of studies to determine whether the presence of antibodies is associated with protection against re-infection with SARS-CoV-2.
A laboratory worker uses a gel electrophoresis analysis machine on a sample from a coronavirus patient who has since recovered from the virus in the virology research labs at UZ Leuven university hospital in Leuven, Belgium, on Friday, Feb. 28, 2020. Photographer: Geert Vanden Wijngaert/Bloomberg

Covid vaccine makers may need to infect subjects to get results

As the infection rate changes, companies running drug trials will face a new problem — not enough test subjects in their regions.
File photo of principal scientific adviser K. VijayRaghavan | @KVijayRaghavan | Twitter

Indian vaccine ventures with global partners could move to human trials soon: VijayRaghavan

At least 14 vaccine candidates being developed solely by Indian players, but none ready for human trials stage yet, Principal Scientific Adviser K. VijayRaghavan says.
A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, US | Bloomberg

Why vaccines should not be immune to market forces

Market prices for vaccines could ensure additional production, help differentiate between vaccines, and even allocation of resources.
European Central Bank (ECB) headquarters | Jasper Juinen/Bloomberg

Green shoots emerge in world economy as virus lockdowns ease

Indicators such as electricity demand and traffic congestions point to a modest 'lift of lows', as economic recovery remains uneven in the absence of a vaccine.
A technician doing an experiment in University of Hong Kong | Paul Yeung | Bloomberg

There will be more than one coronavirus vaccine, and that will be a merry situation

With over 70 vaccine candidates, the end of the Covid crisis will likely be multiple vaccines, some more traditional and others based on emerging technologies.
Representational image | Pixabay

US pharma giant Merck hopes to beat coronavirus with a pill and two vaccines

Merck bought rights to develop a promising antiviral and will work with partners to advance candidate vaccines based on the technology behind Ebola and measles immunizations.

Xi Jinping is seeking to beat Trump in the race for a coronavirus vaccine

China has promised to share any successful vaccine globally, and would wield immense geopolitical clout if it produces one of the world’s first working shots.
A lab worker boxes up test tubes of patient samples in a virology research labs | Geert Vanden Wijngaert | Bloomberg

Chinese vaccine shows promise in early human trial, generates immune response against Covid

The vaccine developed by CanSino Biologics is the first candidate to be tested in human trials.

On Camera

Muslim women walk with their children in Iraq (Representational image) | Commons

Globalisation of revenge

Nobody looks more ridiculous in the whole Iraq situation than the Europeans. A bit of their hypocrisy was on show in New Delhi.
An Airbus Group SE A320neo passenger jet operated by IndiGo

IndiGo to trim fleet size over 2 years as Covid pandemic rages on

IndiGo CEO Ronojoy Dutta said the airline hasn’t engaged in any 'major renegotiation' with Airbus SE on new deliveries, but it will keep returning as many as 40 older planes a year.


File photo of ships during the Malabar naval exercise

First phase of Quad members’ Malabar exercise from 3-6 November in Bay of Bengal

Last week, India had announced Australia will take part in the exercise along with US and Japan, making it a drill by all 4 member nations of the Quad or Quadrilateral coalition.
Illustration: Soham Sen/ThePrint

Trump or Biden? Doesn’t matter to India-US ties as they’re in a full, strategic embrace

Pompeo & Esper’s visit to India for the 2+2 talks is proof that old hypocrisies are history, and supreme national interest has again driven a strategic choice.